Abstract
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is heritable cardiomyopathy that may result in arrhythmia, heart failure, and sudden cardiac death (SCD). Approximately 50–60% of ARVD/C patient will have an identifiable pathogenic mutation in one of seven genes associated with the cardiac desmosome and other cardiac pathways. Genetic counseling remains complicated, however, because of great variable expressivity and reduced penetrance, even within members of the same family. Diagnosis of ARVD/C is made by meeting a set of major and minor diagnostic criteria, revised in 2010. Despite this, misdiagnosis is a chronic problem. Management of ARVD/C is aimed at reducing risk of sudden death/arrhythmias and preventing progression of disease. Strenuous physical activity is increasingly recognized as a significant risk factor in disease presentation and progression and is an important factor in preventative management. Anticipation of the psychosocial implications of this disease is also an important aspect of patient management. This review presents an overview of the clinical diagnosis, management, as well as disease mechanism and genetics of this rare cardiomyopathy.
Similar content being viewed by others
References
Alcalai, R., Metzger, S., Rosenheck, S., Meiner, V., & Chajek-Shaul, T. (2003). A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. Journal of the American College of Cardiology, 16(2), 319–327.
Awad, M. M., Dalal, D., Cho, E., Amat-Alarcon, N., James, C., Tichnell, C., et al. (2006a). DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. American Journal of Human Genetics, 79(1), 136–142.
Awad, M. M., Dalal, D., Tichnell, C., James, C., Tucker, A., Abraham, T., et al. (2006b). Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Human Mutation, 27(11), 1157.
Awad, M. M., Calkins, H., & Judge, D. P. (2008). Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice. Cardiovascular Medicine, 5(5), 258–267.
Basso, C., Thiene, G., Corrado, D., Angelini, A., Nava, A., & Valente, M. (1996). Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation, 94(5), 983–991.
Basso, C., Czarnowska, E., Della Barbera, M., Bauce, B., Beffagna, G., Wlodarska, E. K., Pilichou, K., Ramondo, A., Lorenzon, A., Wozniek, O., Corrado, D., Daliento, L., Danieli, G. A., Valente, M., Nava, A., Thiene, G., & Rampazzo, A. (2006). Ultrastructural evidence of intercalated disc remodeling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. European Heart Journal, 27(15), 1847–1854.
Basso, C., Corrado, D., Marcus, F. I., Nava, A., & Thiene, G. (2009). Arrhythmogenic right ventricular cardiomyopathy. Lancet, 11(9671), 1289–1300.
Basso, C., Bauce, B., Corrado, D., & Thiene, G. (2011). Pathophysiology of arrhythmogenic cardiomyopathy. Nature Reviews Cardiology, [Epub ahead of print].
Bauce, B., Basso, C., Rampazzo, A., Beffagna, G., Daliento, L., Frigo, G., et al. (2005). Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. European Heart Journal, 26(16), 1666–1675.
Bauce, B., Daliento, L., Frigo, G., Russo, G., & Nava, A. (2006). Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 127(2), 186–189.
Bauce, B., Frigo, G., Benini, G., Michieli, P., Basso, C., Folino, A. F., et al. (2010). Differences and similarities between arrhythmogenic right ventricular cardiomyopathy and athlete’s heart adaptations. British Journal of Sports Medicine, 44(2), 148–154.
Beffagna, G., Occhi, G., Nava, A., Vitiello, L., Ditadi, A., Basso, C., et al. (2005). Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovascular Research, 65(2), 366–373.
Bhonsale, A., James, C. A., Tichnell, C., Murray, B., Gagarin, D., Philips, B., et al. (2011). Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. Journal of the American College of Cardiology, 58(14), 1485–1496.
Bierkamp, C., Mclaughlin, K. J., Schwarz, H., Huber, O., & Kemler, R. (1996). Embryonic heart and skin defects in mice lacking plakoglobin. Developmental Biology, 180(2), 780–785.
Bomma, C., Rutberg, J., Tandri, H., Nasir, K., Roguin, A., Tichnell, C., et al. (2004). Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of Cardiovascular Electrophysiology, 15(3), 300–306.
Bonné, S., van Hengel, J., & van Roy, F. (2000). Assignment of the plakophilin-2 gene (PKP2) and a plakophilin-2 pseudogene (PKP2P1) to human chromosome bands 12p11 and 12p13, respectively, by in situ hybridization. Cytogenetics and Cell Genetics, 88(3–4), 286–287.
Bostwich, J. M., & Sola, C. L. (2007). An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. Psychiatric Clinics of North America, 30(4), 677–688.
Burke, A. P., Farb, A., Tashko, G., & Virmani, R. (1998). Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation, 97(16), 1571–1580.
Calabrese, F., Basso, C., Carturan, E., Valente, M., & Thiene, G. (2006). Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiovascular Pathology, 15(1), 11–17.
Calkins, H. (2008). Arrhythmogenic right ventricular dysplasia. Transactions of the American Clinical and Climatological Association, 119, 273–286.
Charron, P., Arad, M., Arbustini, E., Basso, C., Bilinska, Z., Elliott, P., et al. (2010). Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 31(22), 2715–2726.
Coonar, A. S., Protonotarios, N., Tsatsopoulou, A., Needham, E. W., Houlston, R. S., Cliff, S., et al. (1998). Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation, 97(20), 2049–2058.
Corrado, D., & Thiene, G. (2006). Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation, 113(13), 1634–1637.
Corrado, D., Thiene, G., Nava, A., Rossi, L., & Pennelli, N. (1990). Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. American Journal of Medicine, 89, 588–596.
Corrado, D., Basso, C., Thiene, G., McKenna, W. J., Davies, M. J., Fontaliran, F., et al. (1997). Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. Journal of the American College of Cardiology, 30(6), 1512–1520.
Corrado, D., Basso, C., & Thiene, G. (2000). Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart, 83(5), 588–595.
Corrado, D., Basso, C., Rizzoli, G., Schiavon, M., & Thiene, G. (2003a). Does sports activity enhance the risk of sudden death in adolescents and young adults? Journal of the American College of Cardiology, 42, 1959–1963.
Corrado, D., Leoni, L., Link, M. S., Della, B. P., Gaita, F., Curnis, A., et al. (2003b). Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation, 108(25), 3084–3091.
Corrado, D., Basso, C., Leoni, L., Tokajuk, B., Bauce, B., Frigo, G., et al. (2005). Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation, 111(23), 3042–3050.
Corrado, D., Basso, C., & Thiene, G. (2009). Arrhythmogenic right ventricular cardiomyopathy: an update. Heart, 95(9), 766–773.
Corrado, D., Calkins, H., Link, M. S., Leoni, L., Favale, S., Bevilacqua, M., et al. (2010). Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation, 122(12), 1144–1152.
Corrado, D., Basso, C., Pilichou, K., & Thiene, G. (2011). Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart, 97(7), 530–539.
Cox, M. G., van der Zwaag, P. A., van der Werf, C., van der Smagt, J. J., Noorman, M., Bhuiyan, Z. A., et al. (2011). Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation, 123(23), 2690–2700.
Dalal, D., Nasir, K., Bomma, C., Prakasa, K., Tandri, H., Piccini, J., et al. (2005). Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation, 112(25), 3823–3832.
Dalal, D., Molin, L. H., Piccini, J., Tichnell, C., James, C., Bomma, C., et al. (2006). Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation, 113(13), 1641–1649.
Djurdjinovic, L. (1998). Psychosocial counseling. In D. Baker, J. Schuette, & W. R. Uhlmann (Eds.), A guide to genetic counseling (pp. 127–170). Hoboken: Wiley-Liss.
Fabritz, L., Hoogendijk, M. G., Scicluna, B. P., van Amersfoorth, S. C., Fortmueller, L., Wolf, S., et al. (2011). Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. Journal of the American College of Cardiology, 57(6), 740–750.
Frank, R., Fontaine, G., Vedel, J., Mialet, G., Sol, C., Guiraudon, G., et al. (1978). Electrocardiology of 4 cases of right ventricular dysplasia inducing arrhythmia. Archives des Maladies du Coeur et des Vaisseaux, 71(9), 963–972.
Fressart, V., Duthoit, G., Donal, E., Probst, V., Deharo, J. C., Chevalier, P., et al. (2010). Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice. Europace, 12(6), 861–868.
Gallo, P., d’Amati, G., & Pelliccia, F. (1992). Pathologic evidence of extensive left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Hum Pathol, 23(8), 948–952.
Garcia-Gras, E., Lombardi, R., Giocondo, M. J., Willerson, J. T., Schneider, M. D., Khoury, D. S., et al. (2006). Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. The Journal of Clinical Investigation, 116(7), 2012–2021.
Gerull, B., Heuser, A., Wichter, T., Paul, M., Basson, C. T., McDermott, D. A., et al. (2004). Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nature Genetics, 36(11), 1162–1164.
Hamid, M. S., Norman, M., Quraishi, A., Firoozi, S., Thaman, R., Gimeno, J. R., et al. (2002). Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 40(8), 1445–1450.
Heuser, A., Plovie, E. R., Ellinor, P. T., Grossmann, K. S., Shin, J. T., Wichter, T., et al. (2006). Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. American Journal of Human Genetics, 79(6), 1081–1088.
Hodgkinson, K. A., Parfrey, P. S., Bassett, A. S., Kupprion, C., Drenckhahn, J., Norman, M. W., et al. (2005). The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrrhythmogenic right ventricular cardiomyopathy (ARVD5). Journal of the American College of Cardiology, 45(3), 400–408.
James, C. A., Hadley, D. W., Holtzman, N. A., & Winkelstein, J. A. (2006). How does the mode of inheritance of a genetic condition influence families? A study of guilt, blame, stigma, and understanding of inheritance and reproductive risks in families with X-linked and autosomal recessive diseases. Genetics in Medicine, 8(4), 234–242.
James, C. A., Tichnell, C., Murray, B., Daly, A., Sears, S., & Calkins, H. (2012). General and disease-specific psychosocial adjustment in arrhythmogenic right ventricular dysplasia/cardiomyopathy patients with implantable cardioverter defibrillators: a large cohort study. Circulation: Cardiovascular Genetics [in press].
Jonkman, M. F., Pasmooij, A. M., Pasmans, S. G., van den Berg, M. P., Ter Horst, H. J., Timmer, A., et al. (2005). Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. American Journal of Human Genetics, 77(4), 653–660.
Kapplinger, J. D., Landstrom, A. P., Salisbury, B. A., Callis, T. E., Pollevick, G. D., Tester, D. J., et al. (2011). Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. Journal of the American College of Cardiology, 57(23), 2317–2327.
Kirchhof, P., Fabritz, L., Zwiener, M., Witt, H., Schafers, M., Zellerhoff, S., et al. (2006). Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation, 114(17), 1799–1806.
Li, D., Liu, Y., Maruyama, M., Zhu, W., Chen, H., Zhang, W., et al. (2011). Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Human Molecular Genetics, 20(23), 4582–4596.
Lombardi, R., Dong, J., Rodriguez, G., Bell, A., Leung, T. K., & Schwartz, R. J. (2009). Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circulation Research, 104(9), 1076–1084.
Mallat, Z., Tedgui, A., Fontaliran, F., Frank, R., Durigon, M., & Fontaine, G. (1996). Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. The New England Journal of Medicine, 335(16), 1190–1196.
Marcus, F. I., Fontaine, G. H., Guiraudon, G., Frank, R., Laurenceau, J. L., Malergue, C., et al. (1982). Right ventricular dysplasia: a report of 24 adult cases. Circulation, 65(2), 384–398.
Marcus, F. I., Zareba, W., Calkins, H., Towbin, J. A., Basso, C., Bluemke, D. A., et al. (2009). Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm, 6(7), 984–992.
Marcus, F., Basso, C., Gear, K., & Sorrell, V. L. (2010a). Pitfalls in the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. American Journal of Cardiology, 105(7), 1036–1039.
Marcus, F. I., McKenna, W. J., Sherrill, D., Basso, C., Bauce, B., Bluemke, D. A., et al. (2010b). Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. European Heart Journal, 31(7), 806–814.
Maron, B. J., Chaitman, B. R., Ackerman, M. J., Bayés de Luna, A., Corrado, D., Crosson, J. E., et al. (2004). Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation, 109(22), 2807–2816.
McKenna, W. J., Thiene, G., Nava, A., Fontaliran, F., Blomstrom-Lundqvist, C., Fontaine, G., et al. (1994). Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J, 71(3), 215–218.
McKoy, G., Protonotarios, N., Crosby, A., Tsatsopoulou, A., Anastasakis, A., Coonar, A., et al. (2000). Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet, 355(9221), 2119–2124.
Merner, N. D., Hodgkinson, K. A., Haywood, A. F., Connors, S., French, V. M., Drenckhahn, J. D., et al. (2008). Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. American Journal of Human Genetics, 82(4), 809–821.
Nava, A., Thiene, G., & Canciani, B. (1988). Famililal occurrence of right ventricular dysplasia: a study involving nine families. Journal of the American College of Cardiology, 12, 1222–1228.
Nava, A., Bauce, B., Basso, C., Muriago, M., Rampazzo, A., Villanova, C., et al. (2000). Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. Journal of the American College of Cardiology, 36(7), 2226–2233.
Norgett, E. E., Hatsell, S. J., Carvajal-Huerta, L., Cabezas, J. C., Common, J., Purkis, P. E., et al. (2000). Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Human Molecular Genetics, 9(18), 2761–2766.
Norgett, E. E., Lucke, T. W., Bowers, B., Munro, C. S., Leigh, I. M., Kelsell, D. P., et al. (2006). Early death from cardiomyopathy in a family with autosomal dominant striate palmoplantar keratoderma and woolly hair associated with a novel insertion mutation in desmoplakin. The Journal of Investigative Dermatology, 126(7), 1651–1654.
Piccini, J. P., Dalal, D., Roguin, A., Bomma, C., Cheng, A., Prakasa, K., et al. (2005). Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm, 2(11), 1188–1194.
Pilichou, K., Nava, A., Basso, C., Beffagna, G., Bauce, B., Lorenzon, A., et al. (2006). Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation, 113(9), 1171–1179.
Pilichou, K., Remme, C. A., Basso, C., Campian, M. E., Rizzo, S., Barnett, P., et al. (2009). Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. The Journal of Experimental Medicine, 206(8), 1787–1802.
Rampazzo, A., Nava, A., Erne, P., Eberhard, M., Vian, E., Slomp, P., et al. (1995). A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Human Molecular Genetics, 4(11), 2151–2154.
Rampazzo, A., Nava, A., Malacrida, S., Beffagna, G., Bauce, B., Rossi, V., et al. (2002). Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. American Journal of Human Genetics, 71(5), 1200–1206.
Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O’Connell, J., et al. (1995). Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation, 93(5), 841–842.
Roguin, A., Bomma, C. S., Nasir, K., Tandri, H., Tichnell, C., James, C., et al. (2004). Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of the American College of Cardiology, 43(10), 1843–1852.
Sears, S. E., Todaro, J. F., Lewis, T. S., Sotile, W., & Conti, J. B. (1999). Examining the psychosocial impact of implantable cardioverter defibrillators: A literature review. Clinical Cardiology, 22(7), 481–489.
Sen-Chowdhry, S., Lowe, M. D., Sporton, S. C., & McKenna, W. J. (2004). Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. American Journal of Medicine, 117(9), 685–695.
Sen-Chowdhry, S., Syrris, P., & McKenna, W. J. (2005a). Desmoplakin disease in arrhythmogenic right ventricular cardiomyopathy: early genotype-phenotype studies. European Heart Journal, 26(16), 1582–1584.
Sen-Chowdhry, S., Syrris, P., & McKenna, W. J. (2005b). Genetics of right ventricular cardiomyopathy. Journal of Cardiovascular Electrophysiology, 16(8), 927–935.
Sen-Chowdhry, S., Syrris, P., Ward, D., Asimaki, A., Sevdalis, E., & McKenna, W. J. (2007). Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation, 115(13), 1710–1720.
Sen-Chowdhry, S., Syrris, P., Prasad, S. K., Hughes, S. E., Merrifield, R., Ward, D., et al. (2008). Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. Journal of the American College of Cardiology, 52(25), 2175–2187.
Sen-Chowdhry, S., Morgan, R. D., Chambers, J. C., & McKenna, W. J. (2010a). Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annual Review of Medicine, 61, 233–253.
Sen-Chowdhry, S., Syrris, P., Pantazis, A., Quarta, G., McKenna, W. J., & Chambers, J. C. (2010b). Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy. Circulation. Cardiovascular Genetics, 3(4), 323–330.
Syrris, P., Ward, D., Evans, A., Asimaki, A., Gandjbakhch, E., Sen-Chowdhry, S., et al. (2006). Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. American Journal of Human Genetics, 79(5), 978–984.
Tabib, A., Loire, R., Chalabreysse, L., Meyronnet, D., Miras, A., Malicier, D., et al. (2003). Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation, 108(24), 3000–3005.
Tan, H. L., Hofman, N., van Langen, I. M., van der Wal, A. C., & Wilde, A. A. (2005). Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation, 112(2), 207–213.
Taylor, M., Graw, S., Sinagra, G., Barnes, C., Slavov, D., Brun, F., et al. (2011). Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation, 124(8), 876–885.
Tedford, R., James, C., Judge, D., Tichnell, C., Murray, B., Bhonsale, A., et al. (2012). Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of the American College of Cardiology [in press].
Thiene, G., Nava, A., Corrado, D., Rossi, L., & Pennelli, N. (1988). Right ventricular cardiomyopathy and sudden death in young people. The New England Journal of Medicine, 318, 129–133.
Thiene, G., Corrado, D., Nava, A., Rossi, L., Poletti, A., Boffa, G. M., et al. (1991). Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? European Heart Journal, 12(Suppl D), 22–25.
Tiso, N., Stephan, D. A., Nava, A., Bagattin, A., Devaney, J. M., Stanchi, F., et al. (2001). Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Human Molecular Genetics, 10(3), 189–194.
Towbin, J. A. (2008). Arrhythmogenic right ventricular cardiomyopathy: a paradigm of overlapping disorders. Annals of Noninvasive Electrocardiology, 13(4), 325–326.
Uzumcu, A., Norgett, E. E., Dindar, A., Uyguner, O., Nisli, K., et al. (2006). Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. Journal of Medical Genetics, 43(2), 5.
Valente, M., Calabrese, F., Thiene, G., Angelini, A., Basso, C., Nava, A., et al. (1998). In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy. American Journal of Pathology, 152(2), 479–484.
van Tintelen, J. P., Entius, M. M., Bhuiyan, Z. A., Jongbloed, R., Wiesfeld, A. C., Wilde, A. A., et al. (2006). Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation, 113(13), 1650–1658.
van Tintelen, J. P., van Gelder, I. C., Asimaki, A., Suurmeijer, A. J., Wiesfeld, A. C., Jongbloed, J. D., et al. (2009). Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm, 6(11), 1574–1583.
Weil, J. (2002). Genetic counselling in the era of genomic medicine—as we move towards personalised medicine, it becomes more important to help patients understand genetic tests and make complex decisions about their health. EMBO Reports, 3(7), 590–593.
Whittock, N. V., Wan, H., Morley, S. M., Garzon, M. C., Kristal, L., Hyde, P., et al. (2002). Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. The Journal of Investigative Dermatology, 118(2), 232–238.
Wichter, T., & Breithardt, G. (2005). Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: a role for genotyping in decision-making? Journal of the American College of Cardiology, 45(3), 409–411.
Wichter, T., Borggrefe, M., Haverkamp, W., Chen, X., & Breithardt, G. (1992). Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation, 86(1), 29–37.
Wichter, T., Paul, M., Wollmann, C., Acil, T., Gerdes, P., Ashraf, O., et al. (2004). Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation, 109(12), 1503–1508.
Wichter, T., Paul, T. M., Eckardt, L., Gerdes, P., Kirchhof, P., Bocker, D., et al. (2005). Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz, 30(2), 91–101.
Xu, T., Yang, Z., Vatta, M., Rampazzo, A., Beffagna, G., Pilichou, K., et al. (2010). Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. Journal of the American College of Cardiology, 55(6), 587–597.
Yang, Z., Bowles, N. E., Scherer, S. E., Taylor, M. D., Kearney, D. L., Ge, S., et al. (2006). Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation Research, 99(6), 646–655.
Acknowledgements
The ARVD/C program is grateful to the ARVD/C patients and families who have made this work possible. The author would like to also thank the additional genetic counselors in the ARVD/C program at Johns Hopkins: Crystal Tichnell, MGC, and Cynthia James, ScM, PhD, CGC.
Funding Sources
The Johns Hopkins ARVD Program (www.ARVD.com) is supported by the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Wilmerding Endowments, and the Dr. Francis P. Chiaramonte Private Foundation. The author wishes to acknowledge funding to the ARVD Program from the St. Jude Medical Foundation, Medtronic Inc., and Boston Scientific Corp.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murray, B. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C): A Review of Molecular and Clinical Literature. J Genet Counsel 21, 494–504 (2012). https://doi.org/10.1007/s10897-012-9497-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-012-9497-7